Research confirms benefits of side-actuated nasal spray
Valois Pharma's side-actuated nasal spray has excellent ergonomics, is comfortable to handle and easy to actuate, research by the French pharmaceutical company reveals.
The side-actuated nasal spray consists of a standard actuator coupled with a customisable shell and cap.
The research, carried out in the UK last November involving 10 regular nasal spray users, as well as six doctors (GPs and ENT specialists), showed that the side-actuated delivery device has the three advantages mentioned above.
Patients also thought a slightly longer nozzle would improve the placement of the device in the nostril when the device is actuated, and Valois will further investigate this.
The company says new user research will be carried out in the US in the coming months to confirm the results of the current study.
You may also like
Drug Delivery
Hovione and IDC open intranasal dry powder drug delivery platform for commercial partnerships
Read moreHovione and IDC have made their integrated intranasal drug delivery platform available for commercial partnerships, combining API development, particle engineering, drug product manufacturing and a single-use nasal dry powder device to accelerate development and scale-up
Trending Articles
You may also like
Drug Delivery
Hovione and IDC open intranasal dry powder drug delivery platform for commercial partnerships
Hovione and IDC have made their integrated intranasal drug delivery platform available for commercial partnerships, combining API development, particle engineering, drug product manufacturing and a single-use nasal dry powder device to accelerate development and scale-up
Research & Development
From lab to launch: transforming pharmaceutical formulation development with GEA’s CFC Lab Coater
A new generation of continuous film coating technology is giving R&D teams the speed, precision and scalability they need to take products from the laboratory to commercial production without the traditional bottlenecks
Manufacturing
Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target
BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Pharmaceutical
Ardena strengthens executive team to drive its next phase of growth
Ghent, Belgium, 4 May 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointments of Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer. These additions further strengthen Ardena’s executive leadership team as the company continues to scale its operations and commercial reach globally
Pharmaceutical
Backed by investments exceeding $1 billion, PCI Pharma Services announces major expansion of US sterile fill-finish and drug-device delivery combination capabilities
As pharma manufacturers prioritise US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging